世界贸易组织新冠肺炎疫苗知识产权豁免谈判:溯源、诉求与展望  

World Trade Organization Covid-19 Vaccine Intellectual Property Exemption Negotiations:Traceability, Appeals and Prospects

作　　者：孟彦辰[1] Meng Yanchen

机构地区：[1]首都医科大学医学人文学院

出　　处：《国际经济法学刊》2023年第1期56-69,共14页Journal of International Economic Law

基　　金：国家社科基金一般项目“卫生安全视域下我国医疗服务市场扩大开放的风险点与应对机制研究”(21BFX105)的阶段性研究成果。

摘　　要：世界贸易组织的《TRIPS协议》将知识产权作为“私权利”进行保护,有着深刻的历史背景和法理渊源。在新冠疫情全球肆虐、病毒不断变种的今天,全球疫苗产能不足、分配不均、接种不平衡的问题仍然突出。新冠肺炎疫苗的知识产权是一个复杂的体系,而且药品实验数据享有额外的知识产权保护,世界贸易组织成员对于新冠肺炎疫苗知识产权豁免分歧严重,新冠肺炎疫苗知识产权豁免协议短期内难以达成。我国应当在多边层面坚定支持疫苗知识产权豁免,同时也要积极推动双边和区域领域的知识产权谈判,加大对发展中国家的帮扶和统筹协调,推动实现人类卫生健康共同体。The WTO’s TRIPS agreement protects intellectual property rights as a “private right”,and has a profound historical background and legal origin.The intellectual property rights of Covid-19 vaccine is a complex system.Combined with the additional protection of drug trial data and serious differences within its members,it is difficult for the intellectual property exemption agreement of Covid-19 vaccine to reach in the short term.China should firmly support vaccine intellectual property exemption at the multilateral level,and should also actively promote bilateral and regional intellectual property negotiations,increase assistance and coordination to developing countries,and promote the realization of a human health community.

关 键 词：新冠肺炎疫苗 知识产权豁免 《TRIPS协议》 

分 类 号：D997.1[政治法律—国际法学]